Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

Status:	Completed
Conditions:	Neurology, Orthopedic, Women's Studies
Therapuetic Areas:	Neurology, Orthopedics / Podiatry, Reproductive
Healthy:	No
Age Range:	18 - Any
Updated:	2/10/2019
Start Date:	February 2006
End Date:	January 2008

A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia

The aim of this study is to assess longer term safety and effectiveness of Dysport®.

Inclusion Criteria:

- Subjects enrolled in the Y-47-52120-051 study, who have completed all study visits up
to Week 12, or up to Week 4 in the event of an early withdrawal

- Returned to pre-treatment status as judged by the Investigator

Exclusion Criteria:

- Pure anterocollis or pure retrocollis

- Known antibodies to botulinum toxin type A

- Requirement for botulinum toxin injections to site(s) other than the neck and unable
to avoid such treatment for the duration of the study

- Known significant underlying swallowing or respiratory abnormality which might be
exacerbated by botulinum toxin treatment

We found this trial at

sites

University of Florida, Dept of Neurology

Gainesville, Florida 32610

from

Gainesville, FL